HK1089384A1 - Pharmaceutical compositions comprising azd 2171 and zd 6126 and uses thereof - Google Patents

Pharmaceutical compositions comprising azd 2171 and zd 6126 and uses thereof

Info

Publication number
HK1089384A1
HK1089384A1 HK06110018A HK06110018A HK1089384A1 HK 1089384 A1 HK1089384 A1 HK 1089384A1 HK 06110018 A HK06110018 A HK 06110018A HK 06110018 A HK06110018 A HK 06110018A HK 1089384 A1 HK1089384 A1 HK 1089384A1
Authority
HK
Hong Kong
Prior art keywords
azd2171
human
azd
pharmaceutical compositions
antiangiogenic
Prior art date
Application number
HK06110018A
Other languages
English (en)
Inventor
Wedge Stephen Robert
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of HK1089384A1 publication Critical patent/HK1089384A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Iron Core Of Rotating Electric Machines (AREA)
HK06110018A 2003-07-10 2006-09-08 Pharmaceutical compositions comprising azd 2171 and zd 6126 and uses thereof HK1089384A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0316123.9A GB0316123D0 (en) 2003-07-10 2003-07-10 Combination therapy
PCT/GB2004/002937 WO2005004871A1 (en) 2003-07-10 2004-07-07 Combination therapy

Publications (1)

Publication Number Publication Date
HK1089384A1 true HK1089384A1 (en) 2006-12-01

Family

ID=27741905

Family Applications (1)

Application Number Title Priority Date Filing Date
HK06110018A HK1089384A1 (en) 2003-07-10 2006-09-08 Pharmaceutical compositions comprising azd 2171 and zd 6126 and uses thereof

Country Status (18)

Country Link
US (1) US20060160775A1 (de)
EP (1) EP1651227B1 (de)
JP (1) JP2007526887A (de)
KR (1) KR20060034287A (de)
CN (1) CN100435799C (de)
AT (1) ATE385798T1 (de)
AU (1) AU2004255023B2 (de)
BR (1) BRPI0412450A (de)
CA (1) CA2531643A1 (de)
DE (1) DE602004011781T2 (de)
ES (1) ES2299841T3 (de)
GB (1) GB0316123D0 (de)
HK (1) HK1089384A1 (de)
IL (1) IL172682A0 (de)
MX (1) MXPA06000413A (de)
NO (1) NO20056171L (de)
WO (1) WO2005004871A1 (de)
ZA (1) ZA200600188B (de)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0008269D0 (en) * 2000-04-05 2000-05-24 Astrazeneca Ab Combination chemotherapy
GB0310401D0 (en) * 2003-05-07 2003-06-11 Astrazeneca Ab Therapeutic agent
US20080113039A1 (en) * 2004-03-23 2008-05-15 Stephen Robert Wedge Combination Therapy
GB0406445D0 (en) * 2004-03-23 2004-04-28 Astrazeneca Ab Combination therapy
BRPI0612397A2 (pt) * 2005-07-06 2011-02-22 Astrazeneca Ab uso de azd2171 ou um sal farmaceuticamente aceitável do mesmo e gencitabina, composição farmacêutica, kit, e, método para a produção de um efeito anti-angiogênico e/ou redutor da permeabilidade vascular em um animal de sangue quente
BRPI0620118A2 (pt) * 2005-12-22 2011-11-01 Astrazeneca Ab uso de azd2171 ou de um sal farmaceuticamente aceitável do mesmo e de permetrexed, composição farmacêutica, kit, e, método para a produção de um efeito de redução da permeabilidade antiangiogênica, e/ou vascular em um animal de sangue quente
TW200922590A (en) * 2007-09-10 2009-06-01 Curis Inc VEGFR inhibitors containing a zinc binding moiety

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9714249D0 (en) * 1997-07-08 1997-09-10 Angiogene Pharm Ltd Vascular damaging agents
WO1999065515A2 (en) * 1998-06-15 1999-12-23 Arch Development Corporation Combination of radiotherapy and anti-angiogenic factors
PL199802B1 (pl) * 1999-02-10 2008-10-31 Astrazeneca Ab Pochodne chinazoliny, sposoby ich wytwarzania, ich kompozycje farmaceutyczne i ich zastosowania
CZ20023231A3 (cs) * 2000-03-31 2003-01-15 Angiogene Pharmaceuticals Ltd. Farmaceutické prostředky obsahující činidla poąkozující cévy
EE200200565A (et) * 2000-03-31 2004-06-15 Angiogene Pharmaceuticals Ltd. Vaskulaarse kahjustava toimega kombinatsioonravi
GB0008269D0 (en) * 2000-04-05 2000-05-24 Astrazeneca Ab Combination chemotherapy

Also Published As

Publication number Publication date
ZA200600188B (en) 2007-04-25
IL172682A0 (en) 2006-04-10
CN100435799C (zh) 2008-11-26
ES2299841T3 (es) 2008-06-01
WO2005004871A1 (en) 2005-01-20
EP1651227B1 (de) 2008-02-13
CA2531643A1 (en) 2005-01-20
NO20056171L (no) 2006-02-07
KR20060034287A (ko) 2006-04-21
EP1651227A1 (de) 2006-05-03
US20060160775A1 (en) 2006-07-20
AU2004255023B2 (en) 2007-09-27
DE602004011781T2 (de) 2009-02-19
MXPA06000413A (es) 2006-03-17
BRPI0412450A (pt) 2006-09-19
ATE385798T1 (de) 2008-03-15
AU2004255023A1 (en) 2005-01-20
JP2007526887A (ja) 2007-09-20
CN1819830A (zh) 2006-08-16
DE602004011781D1 (de) 2008-03-27
GB0316123D0 (en) 2003-08-13

Similar Documents

Publication Publication Date Title
GB0223380D0 (en) Combination therapy
MX2007003506A (es) Terapia de combinacion de cancer que comprende azd2171 e imatinib.
MX2007003505A (es) Combinacion que comprende zd6474 e imatinib.
MXPA04004355A (es) Tratamiento de combinacion que comprende zd6474 y un taxano.
IL191796A0 (en) Combination of zd6474 and pemetrexed
HRP20080597T3 (en) Cancer combination therapy comprising azd2171 and zd1839
HK1123976A1 (en) Combination of azd2171 and pemetrexed azd2171
HK1089384A1 (en) Pharmaceutical compositions comprising azd 2171 and zd 6126 and uses thereof
HK1096023A1 (en) Combination therapy with azd2171 and 5-fu and/or cpt-11 azd2171?5-fu?cpt-11
MXPA05008583A (es) Terapia de combinacion de zd6474 con 5-fu y/o cpt-11.
WO2005092384A3 (en) Combination therapy with azd2171 and a platinum anti-tumour agent
IL177953A0 (en) Combination therapy including azd2171 and a taxane
GB0223379D0 (en) Combination therapy

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20110707